60 Degrees Pharmaceuticals Q2 2023 Earnings Report $0.85 +0.02 (+2.42%) As of 01/21/2025 04:00 PM Eastern Earnings HistoryForecast 60 Degrees Pharmaceuticals EPS ResultsActual EPS-$1.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/A60 Degrees Pharmaceuticals Revenue ResultsActual Revenue$0.06 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/A60 Degrees Pharmaceuticals Announcement DetailsQuarterQ2 2023Date8/25/2023TimeN/AConference Call ResourcesSXTP Earnings History 60 Degrees Pharmaceuticals Earnings Headlines60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given "Sell (E+)" Rating at Weiss RatingsJanuary 21 at 1:19 AM | americanbankingnews.com60 Degrees Pharmaceuticals' (SXTP) Neutral Rating Reiterated at HC WainwrightJanuary 13, 2025 | americanbankingnews.comElon Musk: my AI will be “worth more than Tesla”Tesla made Elon Musk the richest man in human history. And now, Elon's got a new AI project...January 22, 2025 | Behind the Markets (Ad)60 Degrees Pharmaceuticals enrolls first patient in tafenoquine studyJanuary 9, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisJanuary 8, 2025 | globenewswire.com60 Degrees signs patent license deal with Tufts Medical, says H.C. WainwrightDecember 25, 2024 | markets.businessinsider.comSee More 60 Degrees Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 60 Degrees Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your email. Email Address About 60 Degrees Pharmaceuticals60 Degrees Pharmaceuticals (NASDAQ:SXTP), a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.View 60 Degrees Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings CSX (1/23/2025)Intel (1/23/2025)Texas Instruments (1/23/2025)Freeport-McMoRan (1/23/2025)General Electric (1/23/2025)Union Pacific (1/23/2025)Elevance Health (1/23/2025)Verizon Communications (1/24/2025)NextEra Energy (1/24/2025)American Express (1/24/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
